Cargando…
Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies
In the last 5 years, immune checkpoint antibodies have become established as anticancer agents for various types of cancer. These antibody drugs, namely cytotoxic T‐lymphocyte‐associated antigen, programmed death‐1, and programmed death ligand‐1 antibodies, have revealed relatively high response rat...
Autores principales: | Choudhury, Noura, Nakamura, Yusuke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4768396/ https://www.ncbi.nlm.nih.gov/pubmed/26678880 http://dx.doi.org/10.1111/cas.12862 |
Ejemplares similares
-
Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens
por: Kiyotani, Kazuma, et al.
Publicado: (2018) -
Lymphocyte‐activation gene‐3, an important immune checkpoint in cancer
por: He, Yayi, et al.
Publicado: (2016) -
Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review
por: Onoi, Keisuke, et al.
Publicado: (2020) -
Emerging Immune-Monitoring System for Immune Checkpoint Inhibitors
por: Hamada, Kazuyuki, et al.
Publicado: (2022) -
Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors
por: Gravbrot, Nicholas, et al.
Publicado: (2019)